Retinol-Binding Protein: the Transport Protein for Vitamin a in Human Plasma

Total Page:16

File Type:pdf, Size:1020Kb

Retinol-Binding Protein: the Transport Protein for Vitamin a in Human Plasma Retinol-binding protein: the transport protein for vitamin A in human plasma Masamitsu Kanai, … , Amiram Raz, DeWitt S. Goodman J Clin Invest. 1968;47(9):2025-2044. https://doi.org/10.1172/JCI105889. Research Article Vitamin A circulates in human plasma as retinol bound to a specific transport protein. This protein differs from the known low and high density plasma lipoproteins and has a hydrated density greater than 1.21. In order to study this protein, volunteers were injected intravenously with retinol-15-14C. Plasma was collected 1-3 days later, and the purification of retinol-binding protein (RBP) was monitored by assaying for 14C and also by following the fluorescence of the protein- bound retinol. Purification of RBP was effected by the sequence: Cohn fractionation, chromatography on columns of Sephadex G-200 and diethylaminoethyl (DEAE)-Sephadex, preparative polyacrylamide gel electrophoresis, and finally chromatography on Sephadex G-100. These procedures resulted in a preparation of RBP which was at least 98% pure and which had been purified more than 1500-fold. Purified RBP has α1 mobility on electrophoresis and has a molecular weight of approximately 21,000-22,000. There appears to be one binding site for retinol per molecule of RBP. Solutions of RBP are fluorescent (characteristic of retinol) and have ultraviolet absorption spectra with peaks at 330 mμ (resulting from the bound retinol) and at 280 mμ. There are no fatty acid or fatty acyl chains present in purified RBP. The usual concentration of RBP in plasma is of the order of 3-4 mg/100 ml. In plasma, RBP apparently circulates as a complex, together with another, […] Find the latest version: https://jci.me/105889/pdf Retinol-Binding Protein: the Transport Protein for Vitamin A in Human Plasma MAsAmrrsu KANAI, AMIRAM RAZ, and DEWrrr S. GOODMAN From the Department of Medicine, Columbia University College of Physicians and Surgeons, New York 10032 A BSTRA CT Vitamin A circulates in human fatty acyl chains present in purified RBP. The plasma as retinol bound to a specific transport usual concentration of RBP in plasma is of the protein. This protein differs from the known low order of 3-4 mg/100 ml. In plasma, RBP ap- and high density plasma lipoproteins and has a hy- parently circulates as a complex, together with drated density greater than 1.21. In order to study another, larger protein with prealbumin mobility this protein, volunteers were injected intravenously on electrophoresis. The RBP-prealbumin complex with retinol-15-14C. Plasma was collected 1-3 days remains intact during Cohn fractionation and dur- later, and the purification of retinol-binding pro- ing chromatography on Sephadex and on DEAE- tein (RBP) was monitored by assaying for 14C and Sephadex columns. The complex dissociates dur- also by following the fluorescence of the protein- ing gel electrophoresis, permitting the isolation bound retinol. Purification of RBP was effected by and subsequent purification of each of the com- the sequence: Cohn fractionation, chromatography ponents. The complex is again formed by mixing on columns of Sephadex G-200 and diethylamino- together solutions of the separated RBP and of ethyl (DEAE)-Sephadex, preparative polyacryl- prealbumin. Retinol transport in plasma thus ap- amide gel electrophoresis, and finally chromatog- pears to involve both a lipid-protein (retinol- raphy on Sephadex G-100. These procedures re- RBP) interaction and a protein-protein (RBP- sulted in a preparation of RBP which was at least prealbumin) interaction. 98%o pure and which had been purified more than 1500-fold. Purified RBP has al mobility on elec- INTRODUCTION trophoresis and has a molecular weight of ap- proximately 21,000-22,000. There appears to be It is well established that vitamin A mainly cir- one binding site for retinol per molecule of RBP. culates in plasma as retinol (vitamin A alcohol), Solutions of RBP are fluorescent (characteristic apparently associated with a transport protein of of retinol) and have ultraviolet absorption spectra hydrated density greater than 1.21 (1-3). This with peaks at 330 m~m (resulting from the bound protein differs from serum albumin in man (1) retinol) and at 280 mu. There are no fatty acid or and has been reported to have a, mobility (2) or a2 mobility (4) in the rat. Recently, Alvsaker, This paper is No. 8 in the series "Vitamin A and Haugli, and Laland (5) have suggested that this carotenoids" from the laboratory of DeW. S. Goodman. protein is identical with the tryptophane-rich pre- An abstract of this work was presented to the Seventh International Congress of Biochemistry in Tokyo, Japan, albumin in human serum. Detailed information in August 1967 (39), and the work was presented, in about the transport of retinol in plasma is, how- part, at the 11th International Conference on the Bio- ever, not available. We now report the purification chemistry of Lipids, Jerusalem, Israel, August 1967, and and partial characterization of retinol-binding pro- at the 1968 annual meeting of the American Society for tein (RBP), the specific protein to which retinol Biological Chemists (40). Masamitsu Kanai's permanent address is Shinshu Uni- is bound in human plasma. RBP has-a, mobility versity Hospital, Matsumoto City, Japan. and differs from all previously identified plasma Received for publication 6 February 1968. proteins. The Journal of Clinical Investigation Volume 47 1968 2025 METHODS of 1 mamp per tube at room temperature and was termi- reported here were carried out nated just when the tracking dye ran out of the gel. Plasma. The studies For preparative purposes, the Buchler2 "polyprep" ap- with fresh blood, collected in acid citrate dextrose (ACD) similar to that described adult donors. The iso- paratus was used in a manner anticoagulant, from healthy young by Jovin, Chrambach, and Naughton (9). The prepared lation of RBP was carried out three times: first with cm was prerun for 1 hr at from one donor, second with 1700 ml gel column, about 9.5 high, 280 ml of plasma 30 mamps before the sample was applied. In the usual of plasma from six donors, and third with 5 liters of a of 30-60 mg used in the first of procedure, carried out at 2°-5°C, sample plasma from 16 donors. The plasma of protein was dissolved in 4.5 ml of upper buffer, 0.5 ml these preparations, and 300 ml of the plasma used in the of 40% sucrose solution was added, and the mixed sample second preparation, was derived from subjects previously was then applied to the top of the gel. Electrophoresis injected with "C-labeled retinol. was begun at a current of 15-20 mamps. After 30 min Assay. The purification of RBP was quantitatively 30-35 and was main- each puri- the current was adjusted to mamps monitored by assaying the fractions from tained at this level until the voltage reached 500 volts, fication procedure for protein-bound retinol. In the was continued at a con- carried out by after which time electrophoresis initial stages of this work this assay was stant voltage of 500 volts. The elution rate was 30-40 the extraction of plasma or plasma fractions with CHCI3- ml/hr. The complete procedure usually required 8-10 hr CHaOH, 2:1 (v/v), followed by the chromatography time. During gel electrophoresis the effluent stream was of the total lipid extracts on small columns of deacti- monitored continuously for absorption of light at wave- vated alumina (6) in order to isolate retinol. The retinol length 280 m,.3 The effluent stream from most column was then assayed spectrophotometrically (in our labora- chromatographic runs was similarly monitored. toryEing = 1625 at 330 mg& for retinol in benzene). in most of this work, however, a simpler assay was Paper electrophoresis was performed glycine-ace- During tate buffer, pH 8.6, ionic strength 0.15 (10). Zone elec- used, in which the protein-bound retinol was first labeled Dr. then monitored trophoresis on Pevikon was kindly performed by with '4C, and the purification of RBP was Jane H. Morse, with barbital buffer, pH 8.6, ionic by radioassay, for '4C, of the total lipid extracts. To 0.1 At the end of 1 cm this end, normal volunteers were injected intravenously strength (11). electrophoresis, strips of Pevikon were collected and eluted. The eluates with retinol-15-"'C dispersed in their own plasma. The were analyzed for protein and for 'C (after CHC13- dispersion was achieved by adding, via a microsyringe and under sterile conditions, 0.5 ml of acetone contain- CH30H extraction). ing 12 of retinol-15-"C (specific radioactivity 29.6 Analytical ultracentrifugation. Sedimentation equi- gc librium and velocity analyses were kindly carried out by Ac/mg) to 20 ml of freshly collected plasma. Plasma was E ultra- collected 1-3 days after "C-retinol injection and was Dr. Herbert S. Rosenkranz in a Spinco model was estimated for RBP purification. The radioactivity ("C) in centrifuge. The molecular weight of RBP used method as these plasma samples was shown by extraction and chro- by the sedimentation equilibrium (Archibald) described by Schachman (12). Analyses were carried matography to reside almost entirely in retinol. The "4C ml in 0.05 assay procedure for protein-bound retinol was validated out on a solution of 10 mg of RBP per M po- for each purification method by showing that comparable tassium phosphate buffer, pH 7.2. Centrifugation was con- ducted at 10.6°C at two speeds (9341 and 15,220 rpm), results were obtained by "4C assay and by spectrophoto- Pho- metric assay for retinol. In addition, RBP purification and photographs were taken with Schlieren optics. tographs taken at each speed at bar angles of 70 and of was also qualitatively monitored by observing under ul- with traviolet light the visible, green fluorescence of protein- 80° were measured in a microcomparator, together bound retinol.
Recommended publications
  • Types of Acute Phase Reactants and Their Importance in Vaccination (Review)
    BIOMEDICAL REPORTS 12: 143-152, 2020 Types of acute phase reactants and their importance in vaccination (Review) RAFAAT H. KHALIL1 and NABIL AL-HUMADI2 1Department of Biology, College of Science and Technology, Florida Agricultural and Mechanical University, Tallahassee, FL 32307; 2Office of Vaccines, Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD 20993, USA Received May 10, 2019; Accepted November 25, 2019 DOI: 10.3892/br.2020.1276 Abstract. Vaccines are considered to be one of the most human and veterinary medicine. Proteins which are expressed cost-effective life-saving interventions in human history. in the acute phase are potential biomarkers for the diagnosis The body's inflammatory response to vaccines has both of inflammatory disease, for example, acute phase proteins desired effects (immune response), undesired effects [(acute (APPs) are indicators of successful organ transplantation phase reactions (APRs)] and trade‑offs. Trade‑offs are and can be used to predict the ameliorative effect of cancer more potent immune responses which may be potentially therapy (1,2). APPs are primarily synthesized in hepatocytes. difficult to separate from potent acute phase reactions. The acute phase response is a spontaneous reaction triggered Thus, studying acute phase proteins (APPs) during vaccina- by disrupted homeostasis resulting from environmental distur- tion may aid our understanding of APRs and homeostatic bances (3). Acute phase reactions (APRs) usually stabilize changes which can result from inflammatory responses. quickly, after recovering from a disruption to homeostasis Depending on the severity of the response in humans, these within a few days to weeks; however, APPs expression levels reactions can be classified as major, moderate or minor.
    [Show full text]
  • Alpha1-Antitrypsin, a Reliable Endogenous Marker for Intestinal Protein Loss and Its Application in Patients with Crohn's Disease
    Gut: first published as 10.1136/gut.24.8.718 on 1 August 1983. Downloaded from Gut, 1983, 24, 718-723 Alpha1-antitrypsin, a reliable endogenous marker for intestinal protein loss and its application in patients with Crohn's disease U KARBACH, K EWE, AND H BODENSTEIN From the I. Medizinische Klinik und Poliklinik, Mainz, FR Germany. SUMMARY Intestinal protein loss is generally determined by radio-labelled macromolecules. Alpha1-antitrypsin has been proposed as an endogenous marker for protein losing enteropathy, but different opinions exist about its reliability. In 25 patients with Crohn's disease faecal protein loss was studied with intestinal alpha1-antitrypsin (x1AT) clearance. Simultaneously, in 10 patients x1AT clearance was compared with faecal 51Cr clearance after intravenous 51Cr-albumin injection. There was a linear relation (p<0O05) between X1AT clearance and 51Cr clearance in these cases. In all patients ox1AT clearance was raised above control values. &1AT clearance, however, did not correlate with the activity index of Crohn's disease.1 This index does not contain direct critieria of intestinal inflammation, does not take into account localisation or extent of inflammation, and includes complications such as extraintestinal manifestations, fistuli, stenoses not necessarily related to actual mucosal involvement. It is concluded that x1AT is a reliable marker for intestinal protein loss and that the intestinal changes of Crohn's disease generally lead to an increased protein exudation into the gut. http://gut.bmj.com/ Gastrointestinal loss of plasma proteins can be clearance with the conventional 5 Cr-albumin detected by a variety of labelled macromolecules: method. According to Keaney and Kelleherl° the 59Fe-labelled dextran and 131I_PVP3 are not split by contradictory results could be caused by a difference digestive enzymes; the radioactive isotopes 51Cr- in methods and by comparison of different albumin,4 67Cu-ceruloplasmins or 95Nb-albumin6 are parameters.
    [Show full text]
  • Normal Fibronectin Levels As a Function of Age in the Pediatric Population
    Pediatr. Res. 17: 482-485 (1983) Normal Fibronectin Levels as a Function of Age in the Pediatric Population MICHAEL H. MCCAFFERTY,'~"MARTHA LEPOW, THOMAS M. SABA,'21' ESHIN CHO, HILAIRE MEUWISSEN, JOHN WHITE, AND SHARON F. ZUCKERBROD Departments of Physiology and Pediatrics, Albany Medical College of Union University, Albany, New York, USA Summary pediatric population with age has not been reported. This may be important in terms of appropriate interpretation of prevailing Fibronectin is an important non-immune opsonic protein influ- levels in children with various disease states, because normal encing phagocytic clearance of blood-borne nonbacterial particu- concentrations in children may be different from normal levels in lates which may arise in association with septic shock, tissue adults. This study was designed to measure fibronectin levels in a injury, and intravascular coagulation. In the present study, serum large group (n = 114) of normal children in order to define its fibronectin was measured by both electroimmunoassay as well as normal concentration as a function of age. rapid immunoturbidimetric assay in healthy children (n = 114) ranging in age from 1 month to 15 years in order to delineate the temporal alterations in fibronectin with age. Normal adult serum MATERIALS AND METHODS fibronectin concentrations are typically 220 pg/ml + 20 pg/ml. Serum concentration is 3540% lower than normal plasma con- Healthy children (n = 114) ranging in age from 1 month to 15 centration due to the binding of fibronectin to fibrin during clot years were seen as outpatients or as inpatients for minor surgical formation. Children between 1-12 months of age had significantly procedures.
    [Show full text]
  • Differential Expressions of Plasma Proteins in Systemic Lupus
    Journal of Microbiology, Immunology and Infection (2019) 52, 816e826 Available online at www.sciencedirect.com ScienceDirect journal homepage: www.e-jmii.com Original Article Differential expressions of plasma proteins in systemic lupus erythematosus patients identified by proteomic analysis Rashmi Madda a,1, Shih-Chang Lin a,b,c,1, Wei-Hsin Sun a,**, Shir-Ly Huang d,* a Department of Life Sciences, National Central University, Taiwan b Department of Medicine, College of Medicine, Fu-Jen Catholic University, Taiwan c Division of Rheumatology and Immunology, Cathay General Hospital, Taiwan d Institute of Microbiology and Immunology, National Yang-Ming University, Taiwan Received 27 September 2017; received in revised form 18 January 2018; accepted 21 February 2018 Available online 29 March 2018 KEYWORDS Abstract Introduction: Systemic lupus erythematosus (SLE) is a chronic and complex autoim- Systemic lupus mune disease with a wide range of clinical manifestations that affects multiple organs and tis- erythematosus; sues. Therefore the differential expression of proteins in the serum/plasma have potential Biomarkers; clinical applications when treating SLE. Plasma proteins; Methods: We have compared the plasma/serum protein expression patterns of nineteen active LC-ESI-MS/MS; SLE patients with those of twelve age-matched and gender-matched healthy controls by pro- Lupus: 2D-gel teomic analysis. To investigate the differentially expressed proteins among SLE and controls, a electrophoresis; 2-dimensional gel electrophoresis coupled with high-resolution liquid chromatography tandem Proteomic analysis mass spectrometry was performed. To further understand the molecular and biological func- tions of the identified proteins, PANTHER and Gene Ontology (GO) analyses were employed. Results: A total of 14 significantly expressed (p < 0.05, p < 0.01) proteins were identified, and of these nine were up-regulated and five down-regulated in the SLE patients.
    [Show full text]
  • Ceruloplasmin
    CERULOPLASMIN OSR6164 4 x 18 mL R1 4 x 5 mL R2 Intended Use System reagent for the quantitative determination of Ceruloplasmin (CER) in human serum on Beckman Coulter AU analyzers. Summary Ceruloplasmin is the primary copper containing protein in plasma. It is a late acute phase reactant synthesized by the liver. Acute phase reactant refers to proteins whose serum concentrations rise significantly during acute inflammation due to causes including surgery, myocardial infarction, infections and tumours. Ceruloplasmin’s main clinical importance is in the diagnosis of Wilson’s disease. Here plasma Ceruloplasmin concentration is reduced while dialyzable copper concentration is increased. Increased ceruloplasmin levels are particularly notable in diseases of the reticuloendothelial system such as Hodgkin’s disease as well as during pregnancy or the use of contraceptive pills. Low plasma levels of 1,2 ceruloplasmin are found in malnutrition, malabsorption, nephrosis and severe liver disease, particularly biliary cirrhosis. Methodology Immune complexes formed in solution scatter light in proportion to their size, shape and concentration. Turbidimeters measure the reduction of incident light due to reflection, absorption, or scatter. In the procedure, the measurement of the decrease in light transmitted (increase in absorbance) through particles suspended in solution as a result of complexes formed during the antigen-antibody reaction, is the basis of this assay. System Information For AU400/400e/480, AU600/640/640e/680 and AU2700/5400 Beckman Coulter Analyzers. Reagents Final concentration of reactive ingredients: Solution of Polymers in Phosphate Buffered Saline (pH 7.4 – 7.6) Rabbit anti-human Ceruloplasmin antiserum Also contains preservatives. Precautions 1. For in vitro diagnostic use.
    [Show full text]
  • Clotting Phenomena at the Blood-Polymer Interface and Development of Blood Compatible Polymeric Surfaces
    Clotting Phenomena at the Blood-Polymer Interface and Development of Blood Compatible Polymeric Surfaces Adriaan Bantjes In the past two decades many attempts have been made to relate surface and interfacial parameters with the blood compatibility of polymeric surfaces. It is however doubtful if by a single parameter the behaviour of blood on a surface can be predicted. Two major aspects of blood compatibility -- the prevention of platelet adhesion and the deactivation of the intrinsic coagulation system are determined by the measure and nature of competi- tive blood protein adsorption on the foreign surface. The adhesion of blood platelets is promoted by adsorbed fibrinogen and gamma globulin, while adsorbed albumin inhibits platelct adhesion. Heparinised surfaces do not adsorb fibrin and consequently no adhesion of platelets takes place. Othcr surfaces with low platelct adhesion are the hydrogels, certain block copolyetherurethanes, polyelectrolyte complexes and biolised proteins. Heparinised surfaces of the cationically bonded type inhibit the intrinsic coagulation as well, however this may be due to unstable coatings and heparin leakage. In the authors laboratory a synthetic heparinoid was prepared with the structure - [CH, - C(CH3) NHS03Na ~ C(H) COONa ~ CH2 --] with h, = (7.5 5 1 .O) x lo5 and an in vivo anticoagulant activity of 50% of heparin. Its coatings on PVC, using tridodecyltiietliyl-ammoniuni chloridc as a coupling agent, are stable in plasma and salt solutions and provide surfaces which show negligible platelet adhesion and a strong inhibition 01 the intrinsic coagulation on contact with blood. Similar results were found with polydimethylsiloxane surfaces coated with this heparinoid. 1. INTRODUCTION new blood compatible materials may be developed it is necessary to explain sotne of the mechanisms of blood co- The clinical use of blood contacting devices and prosthcses is agulation on intcraction with a foreign surface.
    [Show full text]
  • The Effect of Gamma Globulin in Pustular Acne*
    PRELIMINARY AND SHORT REPORT THE EFFECT OF GAMMA GLOBULIN IN PUSTULAR ACNE* LOREN W.SHAFFER,M.D., BENJAMIN SdHWIMMER, M.D. AND RENATO J.STANICCO,M.D. One of us (LWS) bad occasion to treat a young Clinical Response: Patient 1: New lesions ceased white man with gamma globulin for prophylaxisappearing immediately after the first injection. after exposure to infectious hepatitis. He wasBy the third week most of the cystic and pustular given two injections, 10 cc. each, of human Polio-lesions had dried up, and no new ones had ap- myelitis Immune Globulin, one week apart. Itpeared. Comedones were not decreased in number. was observed that shortly after the second injec-The patient maintained his improvement through tion, his severe pustular and indurated acnethe fifth week when the cystic and pustular lesions improved considerably. This observation led tobegan to recur. the present study, of which this is a preliminary Patient 2: New lesions continued to develop report. throughout the period of treatment and the one This study of the therapeutic effect of gammamonth follow up. globulin in pustular acne is coupled with a study Patient 3: There was no observable effect of of the serum protein and C-reactive protein levelstreatment. before and after treatment. Patient 4: The first improvement was seen in Method: Four patients in their late teens, other-the second week and by the third, all cystic and wise healthy, but with severe pustular and cysticpustular lesions were dry. The improvement acne that had been resistant to conventionallasted for two weeks after which the lesions methods of treatment were selected for the study.began to return.
    [Show full text]
  • Albumin (Human) 25% Solution, Usp
    PRODUCT MONOGRAPH ALBUMIN (HUMAN) 25% SOLUTION, USP Albumin (Human) 25%, USP Intravenous Solution, 25% Manufacturer’s Standard Plasma Substitute/Blood Derivative Manufactured by: Imported and Distributed by: Date of Approval: Grifols Therapeutics Inc. Grifols Canada Ltd. December 19, 2011 8368 U.S. 70 Bus. Hwy West 5060 Spectrum Way, Clayton, North Carolina Suite 405 27520 Mississauga, Ontario U.S.A. L4W 5N5 Prepared for: Canadian Blood Services Ottawa, Ontario K1G 4J5 Prepared for: Héma-Québec Saint-Laurent, Québec H4R 2W7 Submission Control No: 152126 Page 1 of 19 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION..........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 DESCRIPTION....................................................................................................................3 INDICATIONS AND CLINICAL USE..............................................................................3 CONTRAINDICATIONS ...................................................................................................6 WARNINGS AND PRECAUTIONS..................................................................................6 ADVERSE REACTIONS....................................................................................................7 DRUG INTERACTIONS ....................................................................................................8 DOSAGE AND ADMINISTRATION................................................................................8
    [Show full text]
  • Sex Hormone-Binding Globulin (SHBG) As an Early Biomarker and Therapeutic Target in Polycystic Ovary Syndrome
    International Journal of Molecular Sciences Review Sex Hormone-Binding Globulin (SHBG) as an Early Biomarker and Therapeutic Target in Polycystic Ovary Syndrome Xianqin Qu 1,* and Richard Donnelly 2 1 School of Life Sciences, University of Technology Sydney, Ultimo, NSW 2007, Australia 2 School of Medicine, University of Nottingham, Derby DE22 3DT, UK; [email protected] * Correspondence: [email protected]; Tel.: +61-2-95147852 Received: 1 October 2020; Accepted: 28 October 2020; Published: 1 November 2020 Abstract: Human sex hormone-binding globulin (SHBG) is a glycoprotein produced by the liver that binds sex steroids with high affinity and specificity. Clinical observations and reports in the literature have suggested a negative correlation between circulating SHBG levels and markers of non-alcoholic fatty liver disease (NAFLD) and insulin resistance. Decreased SHBG levels increase the bioavailability of androgens, which in turn leads to progression of ovarian pathology, anovulation and the phenotypic characteristics of polycystic ovarian syndrome (PCOS). This review will use a case report to illustrate the inter-relationships between SHBG, NAFLD and PCOS. In particular, we will review the evidence that low hepatic SHBG production may be a key step in the pathogenesis of PCOS. Furthermore, there is emerging evidence that serum SHBG levels may be useful as a diagnostic biomarker and therapeutic target for managing women with PCOS. Keywords: adolescents; hepatic lipogenesis; human sex hormone-binding globulin; insulin resistance; non-alcoholic fatty liver disease; polycystic ovary syndrome 1. Introduction Polycystic ovary syndrome (PCOS) is a complex, common reproductive and endocrine disorder affecting up to 10% of reproductive-aged women [1].
    [Show full text]
  • Conalbumin More Resistant to Proteolysis and Ther- the Use Of
    IRON AND PROTEIN KINETICS STUDIED BY MEANS OF DOUBLY LABELED HUMAN CRYSTALLINE TRANSFERRIN * BY JAY H. KATZ (From the Radioisotope and Medical Services of the Boston Veterans Administration Hospital, and the Dept. of Medicine, Boston University School of Medicine, Boston, Mass.) (Submitted for publication June 16, 1961; accepted August 10, 1961) Although proteins isotopically labeled with io- demonstrated that not only is the iron complex of dine have been used in tracer studies for some conalbumin more resistant to proteolysis and ther- years, interest has been mainly focused on their mal denaturation than the metal-free protein, but distribution and degradation in the body. While it that it is possible to maintain the iron-binding ca- is often possible to produce iodoproteins whose pacity of the former after extensive iodination. physical and chemical properties are not grossly Since both iron and transferrin levels are af- altered, the possible effects of iodination on the fected in a variety of disease states, a technique functional properties of such substances in a in which both can be followed simultaneously in physiologic setting have been less thoroughly in- vivo should prove valuable. Elmlinger and co- vestigated. That it is possible to trace label pro- workers (18) have reported in abstract form on teins without significantly reducing their biologi- the use of doubly labeled "iron-binding globulin" cal activities has been demonstrated in the case of in human subjects, but few details were given as insulin (2) and certain anterior pituitary hor- to the methods of preparation and the distribution mones (3, 4). of the two labels.
    [Show full text]
  • Ceruloplasmin and Hypoferremia: Studies in Burn and Non-Burn Trauma Patients
    Antioxidants 2015, 4, 153-169; doi:10.3390/antiox4010153 OPEN ACCESS antioxidants ISSN 2076-3921 www.mdpi.com/journal/antioxidants Article Ceruloplasmin and Hypoferremia: Studies in Burn and Non-Burn Trauma Patients Michael A. Dubick 1,*, Johnny L. Barr 1, Carl L. Keen 2 and James L. Atkins 3 1 U.S. Army Institute of Surgical Research, 3698 Chambers Pass, JBSA Fort Sam Houston, TX 78234, USA; E-Mail: [email protected] 2 Departments of Nutrition and Internal Medicine, University of California, Davis, CA 95616, USA; E-Mail: [email protected] 3 Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-210-539-3680. Academic Editor: Nikolai V. Gorbunov Received: 26 November 2014 / Accepted: 28 February 2015 / Published: 6 March 2015 Abstract: Objective: Normal iron handling appears to be disrupted in critically ill patients leading to hypoferremia that may contribute to systemic inflammation. Ceruloplasmin (Cp), an acute phase reactant protein that can convert ferrous iron to its less reactive ferric form facilitating binding to ferritin, has ferroxidase activity that is important to iron handling. Genetic absence of Cp decreases iron export resulting in iron accumulation in many organs. The objective of this study was to characterize iron metabolism and Cp activity in burn and non-burn trauma patients to determine if changes in Cp activity are a potential contributor to the observed hypoferremia. Material and Methods: Under Brooke Army Medical Center Institutional Review Board approved protocols, serum or plasma was collected from burn and non-burn trauma patients on admission to the ICU and at times up to 14 days and measured for indices of iron status, Cp protein and oxidase activity and cytokines.
    [Show full text]
  • Translational Control of Ceruloplasmin Gene Expression: Beyond the IRE
    MAZUMDER ET AL. Biol Res 39, 2006, 59-66 59 Biol Res 39: 59-66, 2006 BR Translational control of ceruloplasmin gene expression: Beyond the IRE BARSANJIT MAZUMDER1, PRABHA SAMPATH2 and PAUL L. FOX3 1Department of Biology, Cleveland State University, Cleveland, OH, 2Department of Pathology, University of Washington, Seattle, WA, USA, and 3Department of Cell Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA ABSTRACT Translational control is a common regulatory mechanism for the expression of iron-related proteins. For example, three enzymes involved in erythrocyte development are regulated by three different control mechanisms: globin synthesis is modulated by heme-regulated translational inhibitor; erythroid 5- aminolevulinate synthase translation is inhibited by binding of the iron regulatory protein to the iron response element in the 5’-untranslated region (UTR); and 15-lipoxygenase is regulated by specific proteins binding to the 3’-UTR. Ceruloplasmin (Cp) is a multi-functional, copper protein made primarily by the liver and by activated macrophages. Cp has important roles in iron homeostasis and in inflammation. Its role in iron metabolism was originally proposed because of its ferroxidase activity and because of its ability to stimulate iron loading into apo-transferrin and iron efflux from liver. We have shown that Cp mRNA is induced by interferon (IFN)-γ in U937 monocytic cells, but synthesis of Cp protein is halted by translational silencing. The silencing mechanism requires binding of a cytosolic inhibitor complex, IFN-Gamma-Activated Inhibitor of Translation (GAIT), to a specific GAIT element in the Cp 3’-UTR. Here, we describe our studies that define and characterize the GAIT element and elucidate the specific trans-acting proteins that bind the GAIT element.
    [Show full text]